25,000 Health Facilities Across India Are Transforming Public Health Systems to Address Growing Critical Climate Issues
7.4.2023 12:00:00 EEST | Business Wire | Press release
In 2021, WHO identified climate change as the biggest global health threat of the 21st century. While half of the world’s population continue to lack access to essential health services, according to a 2019 Health care climate footprint report, if the healthcare sector were a country, it would be the fifth largest greenhouse gas emitter on the planet.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230407005011/en/
Aerial view of Khudei Khunou Health facility in North East India (Photo: Business Wire)
In a significant step towards transforming the public health infrastructure for improved sustainability, SELCO Foundation and IKEA Foundation, in partnership with India’s Ministry of Health and Family Welfare (MOHFW) and various State Health Missions, have launched a groundbreaking initiative ‘Energy for Health’. The program recognises climate adaptation and mitigation at the center to all efforts to upgrade the public health facilities across the world.
Speaking about the significance of this program globally, Dr. Maria Neira, Assistant Director-General a.i., Division of Healthier Populations, and Director, Department of Environment, Climate Change and Health, at the World Health Organization said, “Reliable electricity in health-care facilities is essential to save lives and to provide quality health care. And yet, one billion people around the world are still served by health-care facilities without reliable electricity or with no electricity access at all. Decentralized renewable energies represent a key opportunity to accelerate electrification of health-care facilities, including in remote areas. I congratulate the Government of India and our partners from Selco Foundation and Ikea Foundation for this critical program, which will have a transformative impact on strengthening the health system”.
The first-of-a-kind initiative will bring solar energy solutions with efficient medical and electrical equipment to 25,000 healthcare facilities in 12 states by 2026. Across the 12 states under this program, there is a diversity in terms of topography, socio-economic vulnerabilities, disease burden and climate. This diversity across selected geographies will contribute to this programme serving as a showcase globally- innovating on approaches, models and processes relevant for similar contexts in other parts of the world.
Reflecting on India’s leadership in the effort, Dr. Harish Hande, CEO of SELCO Foundation said, “Affordable and equitable access to healthcare is a function of two aspects- one, resources required to deliver health care, and two, cost of accessing health care. Through this program, SELCO Foundation and IKEA Foundation, along with India’s Ministry of Health and Family Welfare (MOHFW) and various State Health Missions, will showcase at scale how sustainable energy can be used to make health services affordable at the doorstep of the poor.”
‘Energy for Health’ initiative brings with it positive impacts across the spectrum of stakeholders- for last mile communities in their access to timely healthcare; for health facility staff in ensuring a conducive work environment to provide quality services; for health sector in reducing energy and equipment-related costs as well as avoiding wastage of vaccines and other critical resources; reinforcing climate resilience building and carbon mitigation efforts while ensuring positive health outcomes for all citizens.
Mr. Per Heggenes, CEO of IKEA Foundation said, “‘At the IKEA Foundation, we strongly believe caring for the health of people and our planet must go hand-in-hand. This initiative will improve healthcare outcomes and reduce emissions, by providing reliable and renewable energy to thousands of clinics. Our hope is that the success of this programme can serve as a model for building effective and efficient health systems globally.’
Supported by IKEA Foundation, through this initiative, SELCO Foundation along with Government of India will create systems and processes that demonstrate ownership, management, and regular maintenance of the energy systems and appliances. Together, through the 25,000 public health facilities, technical knowledge and capacity, as well as guidelines and policies that enable health staff at different levels to plan for public health infrastructure in a sustainable manner will be improved. The program will also improve the local technical network for solar energy, which could potentially also have indirect impacts on local economies and boost adoption of solar energy across other sectors as well.
The initiative aims to reach over 170 million people across the 12 states and improve working conditions for over 160,000 front line health staff at these health facilities. Across the 25,000 public health facilities, this will add ~100MW of solar energy capacity in the country, and mitigate over 3 million tonnes of CO2e emissions over a 20 year period. These will directly contribute to India’s Net Zero targets, while also creating a paradigm shift on how health targets can be achieved for resource constrained communities across the world in an efficient manner.
About the partners:
SELCO Foundation:
Established in 2010, SELCO Foundation’s mission is to develop holistic solutions that use sustainable energy as a catalyst to address poverty alleviation alongside ensuring environmental sustainability. SELCO's interventions lead to the sustainable delivery of essential services such as healthcare, and enable improvements in livelihoods productivity and till date more than 7 million people have been impacted. The foundation does this by also developing enabling conditions, i.e the ecosystem for sustainable energy solutions to be locally developed, adopted, scaled and institutionalized through stakeholders including government agencies, financiers, local NGOs and enterprises.
For more information, visit www.selco foundation.org, and follow them on Twitter (@SELCOFoundation) and LinkedIn.
IKEA Foundation:
The IKEA Foundation is a strategic philanthropy that focuses its grant making efforts on tackling the two biggest threats to children’s futures: poverty and climate change. It currently grants more than €200 million per year to help improve family incomes and quality of life while protecting the planet from climate change. Since 2009, the IKEA Foundation has granted more than €1.5 billion to create a better future for children and their families.
In 2021 the Board of the IKEA Foundation decided to make an additional €1 billion available over the next five years to accelerate the reduction of Greenhouse Gas emissions.
Learn more at: www.ikeafoundation.org or by following them on LinkedIn or Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230407005011/en/
Contact information
Lotika Mehta
lotika.mehta@ikeafoundation.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 11:15:00 EEST | Press release
Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easier to access, navigate and manage. This will ultimately give pet parents better guidance, greater confidence and more control at every point in
Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
